Investor deep dive
Summit Therapeutics well placed in the race to find next-generation antibiotic
Summit Therapeutics to begin Phase 3 studies of ridinilazol this quarter
Edwards says the company expects to begin treating its first patient this quarter in its Phase 3 study of ridinilazol.
Summit is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary Discuva Platform to expand its pipeline.
Quick facts: Summit Therapeutics PLC